# Byetta

NDC: 0310-6512
Generic name: exenatide
Labeler / Manufacturer: AstraZeneca Pharmaceuticals LP
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: INJECTION
Routes: SUBCUTANEOUS
Marketing started: 20141210
Marketing ended: 20261231
FDA application: NDA021773

## Active ingredients

- EXENATIDE: 250 ug/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0310-6512"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0310-6512
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f